ERBB2 and breast carcinoma: CDK4/6 inhibitors (Goel et al., 2016) can reverse the resistance of HER2-positive breast cancer to anti-HER2-targeted therapy and induce tumor cells to enter cell cycle arrest and have a senescent cell phenotype by inhibiting Rb and S6RP activity.